Status:
UNKNOWN
Chloroquine for Glioblastoma.
Lead Sponsor:
Egyptian Medical Syndicate
Conditions:
Glioblastoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
Adjuvant chloroquine to the conventional treatment for glioblastoma; A randomized, single-blind, placebo-controlled, phase I/II trial.
Eligibility Criteria
Inclusion
- Histologically confirmed glioblastoma Adequate hematologic, hepatic, and renal function Karnofsky performance status score ≥ 70% Life expectancy ≥ six weeks
Exclusion
- Abnormal severe un-controlled medical conditions
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04772846
Start Date
March 1 2018
End Date
March 1 2021
Last Update
February 26 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Private clinics
Cairo, Egypt, 12613